MSI2 and colorectal carcinoma: Moreover, survival analysis was performed by combining MSI2 and HSPB1 expression in CRC patients, and our results demonstrated that patients with high MSI2 and/or HSPB1 expression also had worse prognoses in the CRC TCGA (p = 0.11), GSE17536 (p = 0.0018) and GSE14333 (p = 0.0033) datasets (Fig. 8C).